View Filing Data

This page uses Javascript. Your browser either doesn't support Javascript or you have it turned off. To see this page as it is meant to appear please use a Javascript enabled browser.

Print Document View Excel Document

Document and Entity Information	6 Months Ended
Document and Entity Information	Jun. 30, 2020
Document and Entity Information [Abstract]
Document Type	6-K
Document Period End Date	Jun. 30, 2020
Entity Registrant Name	Genmab A/S
Entity Central Index Key	0001434265
Current Fiscal Year End Date	--12-31
Document Fiscal Year Focus	2020
Document Fiscal Period Focus	Q2
Amendment Flag	false

Consolidated Statements of Comprehensive Income - DKK (kr) kr in Millions	3 Months Ended		6 Months Ended
	Jun. 30, 2020	Jun. 30, 2019	Jun. 30, 2020	Jun. 30, 2019
Income Statement
Revenue	kr 5,451	kr 774	kr 6,343	kr 1,365
Research and development expenses	(775)	(564)	(1,490)	(1,110)
General and administrative expenses	(179)	(73)	(285)	(144)
Operating expenses	(954)	(637)	(1,775)	(1,254)
Operating result	4,497	137	4,568	111
Finance income	42	34	119	98
Finance expenses	(211)	(60)	(5)	(4)
Net result before tax	4,328	111	4,682	205
Corporate tax	(950)	(26)	(1,035)	(48)
Net result	kr 3,378	kr 85	kr 3,647	kr 157
Basic net result per share	kr 51.88	kr 1.38	kr 56.07	kr 2.56
Diluted net result per share	kr 51.35	kr 1.35	kr 55.52	kr 2.53
Statement of Comprehensive Income
Net result	kr 3,378	kr 85	kr 3,647	kr 157
Amounts which may be re-classified to the income statement:
Adjustment of foreign currency fluctuations on subsidiaries	(9)			4
Total comprehensive income	kr 3,369	kr 85	kr 3,647	kr 161

Consolidated Balance Sheets - DKK (kr) kr in Millions	Jun. 30, 2020	Dec. 31, 2019
Consolidated Balance Sheets
Intangible assets	kr 413	kr 470
Property, plant and equipment	414	237
Right-of-use assets	312	177
Receivables	12	11
Deferred tax assets	239	139
Other investments	152	149
Total non-current assets	1,542	1,183
Receivables	6,359	2,990
Marketable securities	6,177	7,419
Cash and cash equivalents	6,605	3,552
Total current assets	19,141	13,961
Total assets	20,683	15,144
SHAREHOLDERS' EQUITY AND LIABILITIES
Share capital	65	65
Share premium	11,826	11,755
Other reserves	98	98
Retained Earnings	5,882	2,130
Shareholders' equity	17,871	14,048
Provisions	2	2
Lease liabilities	313	155
Deferred revenue	487
Other payables	1	1
Total non-current liabilities	803	158
Corporate tax payable	1,085	73
Lease liabilities	43	26
Deferred revenue	26
Other payables	855	839
Total current liabilities	2,009	938
Total liabilities	2,812	1,096
Total shareholders' equity and liabilities	kr 20,683	kr 15,144

Consolidated Statements of Cash Flows - DKK (kr) kr in Millions	6 Months Ended
	Jun. 30, 2020	Jun. 30, 2019
Cash flows from operating activities:
Net result before tax	kr 4,682	kr 205
Reversal of financial items, net	(114)	(94)
Adjustment for non-cash transactions	182	136
Changes in operating assets and liabilities	(2,570)	700
Cash flow from operating activities before financial items	2,180	947
Interest received	77	30
Interest elements of lease payments	(3)	(4)
Interest paid	(4)	(1)
Corporate taxes paid	(97)	(140)
Net cash generated by operating activities	2,153	832
Cash flows from investing activities:
Investment in intangible assets	(203)	(36)
Marketable securities bought	(3,006)	(2,215)
Marketable securities sold	4,137	1,465
Net cash used in investing activities	928	(786)
Cash flows from financing activities:
Warrants exercised	54	38
Shares issued for cash		1
Principal elements of lease payments	(17)	(14)
Payment of withholding taxes on behalf of employees on net settled RSUs	(18)	(9)
Net cash from financing activities	19	16
Changes in cash and cash equivalents	3,100	62
Cash and cash equivalents at the beginning of the period	3,552	533
Exchange rate adjustments	(47)	(12)
Cash and cash equivalents at the end of the period	6,605	583
Cash and cash equivalents include:
Bank deposits and petty cash	3,602	kr 583
Short-term marketable securities	kr 3,003

Consolidated Statements of Changes in Equity - DKK (kr) kr in Millions	Share capital	Share premium [Member]	Translation reserves	Retained Earnings [Member]	Total
Balance at beginning of period at Dec. 31, 2018	kr 61	kr 8,059	kr 92	kr (198)	kr 8,014
Net result				157	157
Other comprehensive income			4		4
Total comprehensive income			4	157	161
Transactions with owners:
Exercise of warrants	1	38			39
Share-based compensation expenses				68	68
Net settlement of RSUs				(9)	(9)
Tax on items recognized directly in equity				14	14
Balance at end of period at Jun. 30, 2019	62	8,097	96	32	8,287
Balance at beginning of period at Dec. 31, 2019	65	11,755	98	2,130	14,048
Net result				3,647	3,647
Total comprehensive income				3,647	3,647
Transactions with owners:
Exercise of warrants		71			71
Share-based compensation expenses				98	98
Net settlement of RSUs				(18)	(18)
Tax on items recognized directly in equity				25	25
Balance at end of period at Jun. 30, 2020	kr 65	kr 11,826	kr 98	kr 5,882	kr 17,871

Subsequent Events to the Balance Sheet Date	6 Months Ended
Subsequent Events to the Balance Sheet Date	Jun. 30, 2020
Subsequent Events to the Balance Sheet Date
Subsequent Events to the Balance Sheet Date	Note 8 - Subsequent Events to the Balance Sheet Date No events have occurred subsequent to the balance sheet date that could significantly affect the financial statements as of June 30, 2020.

Basis of Presentation - Fair Value Measurement (Details) - DKK (kr) kr in Millions	Jun. 30, 2020	Dec. 31, 2019
Basis of Presentation
Marketable securities	kr 6,177	kr 7,419
Other investments	152	149
Level 1
Basis of Presentation
Marketable securities	6,177	7,419
Level 3
Basis of Presentation
Other investments	kr 152	149
Level 3 \| Cure Vac AG [Member]
Basis of Presentation
Other investments		kr 149

Revenue (Details) - DKK (kr) kr in Millions	6 Months Ended
Revenue (Details) - DKK (kr) kr in Millions	Jun. 30, 2020	Jun. 30, 2019
Revenue
Revenue	kr 6,343	kr 1,365
Janssen
Revenue
Revenue	1,652	1,189
AbbVie
Revenue
Revenue	4,398
Seattle Genetics
Revenue
Revenue	99	111
BioNTech
Revenue
Revenue	76	53
Other collaboration partners
Revenue
Revenue	118	12
Royalties
Revenue
Revenue	1,738	1,181
Milestone payments
Revenue
Revenue	32	20
License fees
Revenue
Revenue	4,398
Reimbursement income
Revenue
Revenue	kr 175	kr 164

Revenue - AbbVie Collaboration Agreement (Details) - Jun. 10, 2020 - AbbVie kr in Millions, $ in Millions	USD ($) item	DKK (kr) item
Disclosure of disaggregation of revenue from contracts with customers [line items]
Upfront payment	$ 750
Ratio of share of profits before income taxes	50.00
Percentage of discover research and development cost responsible by the entity	100.00%	100.00%
Number of performance obligations \| item	4	4
Contract transaction price	$ 750	kr 4,911
Revenue from performance obligations satisfied or partially satisfied in previous periods \| kr		kr 0
Performance obligation Revenue recognition period	7 years	7 years
Number of delivery license programs \| item	3
Performance obligations satisfied at point in time
Disclosure of disaggregation of revenue from contracts with customers [line items]
Contract transaction price	$ 672	kr 4,398
Performance obligations satisfied over time
Disclosure of disaggregation of revenue from contracts with customers [line items]
Contract transaction price	$ 78	kr 513
Maximum \| Countries Outside United States and Japan
Disclosure of disaggregation of revenue from contracts with customers [line items]
Royalty percent on sales	26.00%
Minimum \| Countries Outside United States and Japan
Disclosure of disaggregation of revenue from contracts with customers [line items]
Royalty percent on sales	22.00%
Development Regulatory and Sales Milestone \| Clinical Development and Commercial Success Across all Three Programs
Disclosure of disaggregation of revenue from contracts with customers [line items]
Receivables	$ 1,150
Development Regulatory and Sales Milestone \| Success of all Four Next Generation Antibody Product Candidates Developed
Disclosure of disaggregation of revenue from contracts with customers [line items]
Receivables	2,000
Development Regulatory and Sales Milestone \| Maximum
Disclosure of disaggregation of revenue from contracts with customers [line items]
Receivables	$ 3,150

Marketable Securities (Details) - DKK (kr) kr in Millions	6 Months Ended	12 Months Ended
Marketable Securities (Details) - DKK (kr) kr in Millions	Jun. 30, 2020	Dec. 31, 2019	Jun. 30, 2020	Dec. 31, 2019
Marketable Securities
Cost at the beginning of the period	kr 15,144
Cost at the end of the period	20,683	kr 15,144
Net book value at the end of the period	20,683	15,144	kr 20,683	kr 15,144
Triple A-rating from Moody's, S&P or Fitch
Marketable Securities
Percentage of marketable securities			89.00%	91.00%
Marketable Securities
Marketable Securities
Fair value adjustment at the beginning of the period	39	79
Fair value adjustment for the period	(96)	(40)
Fair value adjustment at the end of the period	kr (57)	kr 39
Average effective duration	1 year 4 days	1 year 26 days
Cost \| Marketable Securities
Marketable Securities
Cost at the beginning of the period	kr 7,380	kr 5,494
Additions for the period	3,006	5,812
Disposals and maturities for the period	(4,152)	(3,926)
Cost at the end of the period	6,234	7,380
Net book value at the end of the period	6,234	7,380	kr 6,234	kr 7,380
Net Book value \| Marketable Securities
Marketable Securities
Cost at the beginning of the period	7,419
Cost at the end of the period	6,177	7,419
Net book value at the end of the period	kr 6,177	kr 7,419	kr 6,177	kr 7,419
Net book value in percentage of cost			99.00%	101.00%

Share-Based Instruments - Part 1 (Details) kr in Millions	6 Months Ended
Share-Based Instruments - Part 1 (Details) kr in Millions	Jun. 30, 2020 DKK (kr) kr / shares	Jun. 30, 2019 DKK (kr) kr / shares
Disclosure of terms and conditions of share-based payment arrangement [line items]
Outstanding at beginning of period	307,907	218,902
Granted	22,672	15,431
Vested	(39,438)	(22,189)
Forfeited/Cancelled	(6,494)	(5,053)
Outstanding at end of period	284,647	207,091
RSUs
Disclosure of terms and conditions of share-based payment arrangement [line items]
Granted	22,672	15,431
Vested	(39,438)	(22,189)
Weighted average fair value of RSU granted \| kr / shares	kr 1,491.16	kr 1,154.35

Shareholdings by the board of Directors and Executive Management (Details) kr in Millions	6 Months Ended
	Jun. 30, 2020 EquityInstruments DKK (kr) shares	Jun. 30, 2019 DKK (kr) shares
Shareholdings By Board Of Directors And Executive Management [Line items]
Granted	49,323	49,360
Exercised	(272,078)	(192,572)
Outstanding at beginning of period \| kr	307,907	218,902
Granted \| kr	22,672	15,431
Outstanding at end of period \| kr	284,647	207,091
Board of Directors And Executive Management [Member]
Shareholdings By Board Of Directors And Executive Management [Line items]
Balance at beginning of period	799,435
Acquired	12,700
Sold	3,671
Transfers	(113,494)
Balance at end of period	694,970
Balance at beginning of period	410,135
Granted	7,771
Exercised	(16,938)
Cancelled	(28,424)
Transfers	(206,333)
Balance at end of period	166,211
Board of Directors
Shareholdings By Board Of Directors And Executive Management [Line items]
Balance at beginning of period	50,690
Acquired	6,588
Sold	3,671
Transfers	(32,320)
Balance at end of period	21,287
Balance at beginning of period	62,334
Exercised	(16,938)
Transfers	(20,000)
Balance at end of period	25,396
Mats Pettersson
Shareholdings By Board Of Directors And Executive Management [Line items]
Balance at beginning of period	32,007
Acquired	786
Transfers	(32,793)
Balance at beginning of period	20,000
Transfers	(20,000)
Anders Gersel Pedersen
Shareholdings By Board Of Directors And Executive Management [Line items]
Balance at beginning of period	8,718
Acquired	589
Balance at end of period	9,307
Balance at beginning of period	20,000
Exercised	(10,000)
Balance at end of period	10,000
Pernille Erenbjerg
Shareholdings By Board Of Directors And Executive Management [Line items]
Balance at beginning of period	3,178
Acquired	393
Balance at end of period	3,571
Paolo Paoletti
Shareholdings By Board Of Directors And Executive Management [Line items]
Balance at beginning of period	3,337
Acquired	393
Sold	2,700
Balance at end of period	1,030
Rolf Hoffmann
Shareholdings By Board Of Directors And Executive Management [Line items]
Balance at beginning of period	1,050
Acquired	1,121
Balance at end of period	2,171
Deirdre P. Connelly
Shareholdings By Board Of Directors And Executive Management [Line items]
Balance at beginning of period	2,200
Acquired	1,121
Balance at end of period	3,321
Jonathan Peacock
Shareholdings By Board Of Directors And Executive Management [Line items]
Transfers	473
Balance at end of period	473
Peter Storm Kristensen
Shareholdings By Board Of Directors And Executive Management [Line items]
Balance at beginning of period	200
Acquired	1,071
Sold	971
Balance at end of period	300
Balance at beginning of period	2,383
Exercised	(563)
Balance at end of period	1,820
Mijke Zachariasse
Shareholdings By Board Of Directors And Executive Management [Line items]
Acquired	34
Balance at end of period	34
Balance at beginning of period	908
Balance at end of period	908
Daniel Bruno
Shareholdings By Board Of Directors And Executive Management [Line items]
Acquired	1,080
Balance at end of period	1,080
Balance at beginning of period	19,043
Exercised	(6,375)
Balance at end of period	12,668
Executive Management
Shareholdings By Board Of Directors And Executive Management [Line items]
Balance at beginning of period	748,745
Acquired	6,112
Transfers	(81,174)
Balance at end of period	673,683
Balance at beginning of period	347,801
Granted	7,771
Cancelled	(28,424)
Transfers	(186,333)
Balance at end of period	140,815
Jan van de Winkel
Shareholdings By Board Of Directors And Executive Management [Line items]
Balance at beginning of period	668,484
Acquired	2,939
Balance at end of period	671,423
Balance at beginning of period	65,668
Balance at end of period	65,668
David A. Eatwell
Shareholdings By Board Of Directors And Executive Management [Line items]
Balance at beginning of period	80,261
Acquired	1,776
Transfers	(82,037)
Balance at beginning of period	245,201
Cancelled	(28,424)
Transfers	(216,777)
Anthony Pagano
Shareholdings By Board Of Directors And Executive Management [Line items]
Transfers	863
Balance at end of period	863
Transfers	30,444
Balance at end of period	30,444
Judith Klimovsky
Shareholdings By Board Of Directors And Executive Management [Line items]
Acquired	1,397
Balance at end of period	1,397
Balance at beginning of period	36,932
Balance at end of period	36,932
Anthony Mancini
Shareholdings By Board Of Directors And Executive Management [Line items]
Granted	7,771
Balance at end of period	7,771
RSUs
Shareholdings By Board Of Directors And Executive Management [Line items]
Granted \| kr	22,672	15,431
RSUs \| Board of Directors And Executive Management [Member]
Shareholdings By Board Of Directors And Executive Management [Line items]
Outstanding at beginning of period \| EquityInstruments	92,818
Granted \| EquityInstruments	10,206
Settled	(18,723)
Cancelled	(1,128)
Transfers	(4,384)
Outstanding at end of period \| EquityInstruments	78,789
RSUs \| Board of Directors
Shareholdings By Board Of Directors And Executive Management [Line items]
Outstanding at beginning of period \| EquityInstruments	19,953
Granted \| EquityInstruments	1,174
Settled	(6,470)
Transfers	(2,050)
Outstanding at end of period \| EquityInstruments	12,607
RSUs \| Mats Pettersson
Shareholdings By Board Of Directors And Executive Management [Line items]
Outstanding at beginning of period \| EquityInstruments	2,836
Settled	(786)
Transfers	(2,050)
RSUs \| Anders Gersel Pedersen
Shareholdings By Board Of Directors And Executive Management [Line items]
Outstanding at beginning of period \| EquityInstruments	1,807
Settled	(589)
Outstanding at end of period \| EquityInstruments	1,218
RSUs \| Pernille Erenbjerg
Shareholdings By Board Of Directors And Executive Management [Line items]
Outstanding at beginning of period \| EquityInstruments	1,418
Settled	(393)
Outstanding at end of period \| EquityInstruments	1,025
RSUs \| Paolo Paoletti
Shareholdings By Board Of Directors And Executive Management [Line items]
Outstanding at beginning of period \| EquityInstruments	1,418
Settled	(393)
Outstanding at end of period \| EquityInstruments	1,025
RSUs \| Rolf Hoffmann
Shareholdings By Board Of Directors And Executive Management [Line items]
Outstanding at beginning of period \| EquityInstruments	2,146
Settled	(1,121)
Outstanding at end of period \| EquityInstruments	1,025
RSUs \| Deirdre P. Connelly
Shareholdings By Board Of Directors And Executive Management [Line items]
Outstanding at beginning of period \| EquityInstruments	2,465
Settled	(1,121)
Outstanding at end of period \| EquityInstruments	1,344
RSUs \| Jonathan Peacock
Shareholdings By Board Of Directors And Executive Management [Line items]
Granted \| EquityInstruments	1,174
Outstanding at end of period \| EquityInstruments	1,174
RSUs \| Peter Storm Kristensen
Shareholdings By Board Of Directors And Executive Management [Line items]
Outstanding at beginning of period \| EquityInstruments	1,832
Settled	(508)
Outstanding at end of period \| EquityInstruments	1,324
RSUs \| Mijke Zachariasse
Shareholdings By Board Of Directors And Executive Management [Line items]
Outstanding at beginning of period \| EquityInstruments	534
Settled	(75)
Outstanding at end of period \| EquityInstruments	459
RSUs \| Daniel Bruno
Shareholdings By Board Of Directors And Executive Management [Line items]
Outstanding at beginning of period \| EquityInstruments	5,497
Settled	(1,484)
Outstanding at end of period \| EquityInstruments	4,013
RSUs \| Executive Management
Shareholdings By Board Of Directors And Executive Management [Line items]
Outstanding at beginning of period \| EquityInstruments	72,865
Granted \| EquityInstruments	9,032
Settled	(12,253)
Cancelled	(1,128)
Transfers	(2,334)
Outstanding at end of period \| EquityInstruments	66,182
RSUs \| Jan van de Winkel
Shareholdings By Board Of Directors And Executive Management [Line items]
Outstanding at beginning of period \| EquityInstruments	37,597
Settled	(5,819)
Outstanding at end of period \| EquityInstruments	31,778
RSUs \| David A. Eatwell
Shareholdings By Board Of Directors And Executive Management [Line items]
Outstanding at beginning of period \| EquityInstruments	12,375
Settled	(3,634)
Cancelled	(1,128)
Transfers	(7,613)
RSUs \| Anthony Pagano
Shareholdings By Board Of Directors And Executive Management [Line items]
Granted \| EquityInstruments	2,295
Transfers	5,279
Outstanding at end of period \| EquityInstruments	7,574
RSUs \| Judith Klimovsky
Shareholdings By Board Of Directors And Executive Management [Line items]
Outstanding at beginning of period \| EquityInstruments	22,893
Settled	(2,800)
Outstanding at end of period \| EquityInstruments	20,093
RSUs \| Anthony Mancini
Shareholdings By Board Of Directors And Executive Management [Line items]
Granted \| EquityInstruments	6,737
Outstanding at end of period \| EquityInstruments	6,737

Leases - Total cash outflow for leases (Details) kr in Millions	Jun. 30, 2020 DKK (kr)
OPERATING ASSETS AND LIABILITIES
Lease liabilities	kr 181
Lease liabilities	kr 356